RT Journal Article
T1 Evaluation of Polysaccharide Typhim Vi Antibody Response as a predictor of Humoral Immunodeficiency in Haematological Malignancies
A1 Ochoa-Grullón, J. et al.
A1 S. Sánchez-Ramón, 
A1 Benavente Cuesta, Celina
A1 Pérez López, César
A1 Peña Cortijo, Ascensión
A1 Mateos-Aparicio Morales, Gregoria
A1 Williams, J.L.
A1 Fernández Arquero, Miguel
A1 Recio Hoyas, María José
AB An increasing healthcare challenge in the management of haematological malignancy (HM) is secondary immunodeficiency. From January 2019, the EMA included the evaluation of specific antibody (Ab) responses to better select patients for immunoglobulin replacement therapy (IgRT). We evaluated Ab responses to pneumococcal and Salmonella typhi pure polysaccharide immunization in a cohort of 42 HM patients and 24 healthy-controls. Pre-post specific Ab concentrations were measured by ELISA at 4 weeks. Globally, significantly lower Typhim Vi (TV) seroprevalence (9%) compared to 23-valent pneumococcal polysaccharide vaccine (PPV) (76%) (p <0.001) was observed. TV non responders (88%) were higher than PPV non responders (62%) (p <0.0001) and correlated better to infectious history. By ROC analysis, pre-post 5-fold TV increase was the best cut-off to discriminate HM with recurrent infections and controls (sensitivity 91%, specificity 100%). Despite the small sample cohort, our results suggest that specific anti-S typhi Ab response is a useful complementary assay in the diagnosis and management decision of SID to HM.
PB ACADEMIC PRESS INC ELSEVIER SCIENCE
SN 1521-6616
YR 2020
FD 2020-01
LK https://hdl.handle.net/20.500.14352/92618
UL https://hdl.handle.net/20.500.14352/92618
LA eng
NO Ochoa-Grullón J, Benavente Cuesta C, Pérez López C, Peña Cortijo A, Rodríguez de la Peña A, Álvarez Carmona A, Mateo Morales M, Llano-Hernández K, Williams LJ, Rodríguez de Frías E, Guevara-Hoyer K, Cordero Torres G, Orte C, Fernández-Arquero M, Fernández-Paredes L, Serrano-García I, Recio MJ, Pérez de Diego R, Martínez R, Sánchez-Ramón S. Clin Immunol. 2020 Jan;210:108307.
DS Docta Complutense
RD 20 ago 2024